Serine
Serine is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against interleukin-17A. In addition, it is known to target metabotropic glutamate receptor 4, probable G-protein coupled receptor 34, probable G-protein coupled receptor 174, metabotropic glutamate receptor 6, neutral amino acid transporter B(0), G-protein coupled receptor family C group 6 member A, sodium- and chloride-dependent glycine transporter 2, glutamate receptor ionotropic, NMDA 1, potassium voltage-gated channel subfamily A member 1, glutamate receptor ionotropic, NMDA 2D, glutamate receptor ionotropic, NMDA 2A, metabotropic glutamate receptor 8, metabotropic glutamate receptor 7, toll-like receptor 4, glutamate receptor ionotropic, NMDA 2C, and glutamate receptor ionotropic, NMDA 2B.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| aminosyn ii | New Drug Application | 2022-05-04 |
| aminosyn-pf | New Drug Application | 2022-07-21 |
| clinimix | New Drug Application | 2021-04-13 |
| clinimix e | New Drug Application | 2021-04-13 |
| clinisol | ANDA | 2018-06-01 |
| enbrace hr | unapproved drug other | 2025-01-02 |
| enlyte | unapproved drug other | 2022-07-01 |
| kabiven | New Drug Application | 2025-09-11 |
| paxlyte | unapproved drug other | 2024-12-19 |
| perikabiven | New Drug Application | 2025-09-15 |
Show 5 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
767 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stroke | D020521 | EFO_0000712 | I63.9 | 7 | 23 | 39 | 8 | 19 | 92 |
| Ischemic stroke | D000083242 | — | — | 5 | 26 | 42 | 12 | 14 | 90 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 5 | 13 | 5 | 4 | 4 | 27 |
| Neoplasms | D009369 | — | C80 | 16 | 8 | 1 | 1 | 6 | 26 |
| Pulmonary embolism | D011655 | EFO_0003827 | I26 | — | 4 | 8 | 10 | 3 | 25 |
| Thrombosis | D013927 | — | — | 3 | 3 | 10 | 6 | 5 | 25 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | 3 | 10 | 6 | 6 | 24 |
| Ischemia | D007511 | EFO_0000556 | — | 4 | 6 | 8 | 3 | 3 | 23 |
| Covid-19 | D000086382 | — | U07.1 | 2 | 15 | 6 | 1 | 3 | 21 |
| Orthostatic hypotension | D007024 | — | I95.1 | 2 | 4 | 9 | 4 | 1 | 18 |
Show 98 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 3 | 3 | 2 | — | 4 | 12 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | 3 | 1 | — | 5 | 9 |
| Cerebral hemorrhage | D002543 | — | — | — | 3 | 2 | — | 3 | 8 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 1 | 3 | 1 | — | 3 | 8 |
| Non-small-cell lung carcinoma | D002289 | — | — | 5 | 3 | 1 | — | — | 7 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | 1 | 4 | 2 | — | — | 6 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 1 | 4 | — | 1 | 6 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | 2 | 2 | 2 | — | 1 | 6 |
| Cerebrovascular disorders | D002561 | EFO_0003763 | I60-I69 | 1 | 3 | 2 | — | — | 5 |
| Pain | D010146 | EFO_0003843 | R52 | — | 3 | 2 | — | 1 | 5 |
Show 99 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 7 | 1 | — | — | 5 | 13 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 2 | 5 | — | — | 2 | 9 |
| Carcinoma | D002277 | — | C80.0 | 4 | 1 | — | — | 1 | 5 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 2 | 2 | — | — | 1 | 5 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 2 | 3 | — | — | — | 5 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 2 | 2 | — | — | 2 | 5 |
| Depression | D003863 | — | F33.9 | 1 | 2 | — | — | 2 | 5 |
| Cocaine-related disorders | D019970 | — | F14 | — | 4 | — | — | 1 | 5 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | 2 | 2 | — | — | — | 4 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | 2 | — | — | 2 | 4 |
Show 120 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | — | — | 4 | 5 |
| Esophageal neoplasms | D004938 | — | C15 | 1 | — | — | — | 2 | 3 |
| Multiple myeloma | D009101 | — | C90.0 | 2 | — | — | — | — | 2 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 2 | — | — | — | — | 2 |
| Retinal vein occlusion | D012170 | EFO_1001157 | H34.81 | 2 | — | — | — | — | 2 |
| Tobacco use disorder | D014029 | — | F17 | 2 | — | — | — | — | 2 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 2 | — | — | — | — | 2 |
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | — | 1 |
| Medical sociology | D012962 | — | — | 1 | — | — | — | — | 1 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | — | — | — | — | 1 |
Show 32 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver transplantation | D016031 | EFO_0010682 | — | — | — | — | — | 3 | 3 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | — | — | 3 | 3 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 3 | 3 |
| Pancreatitis | D010195 | EFO_0000278 | K85 | — | — | — | — | 2 | 2 |
| Chronic pancreatitis | D050500 | EFO_0000342 | K86.1 | — | — | — | — | 2 | 2 |
| Tobacco smoking | D000073869 | — | — | — | — | — | — | 2 | 2 |
| Mutagenesis | D016296 | — | — | — | — | — | — | 2 | 2 |
| Tic disorders | D013981 | — | F95 | — | — | — | — | 2 | 2 |
| Aneurysm | D000783 | — | I72.9 | — | — | — | — | 2 | 2 |
| Human influenza | D007251 | EFO_0007328 | J11.1 | — | — | — | — | 2 | 2 |
Show 96 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Serine |
| INN | dexfosfoserine |
| Description | L-serine is the L-enantiomer of serine. It has a role as a human metabolite, an algal metabolite, a Saccharomyces cerevisiae metabolite, an Escherichia coli metabolite and a mouse metabolite. It is a serine family amino acid, a proteinogenic amino acid, a L-alpha-amino acid and a serine. It is a conjugate base of a L-serinium. It is a conjugate acid of a L-serinate. It is an enantiomer of a D-serine. It is a tautomer of a L-serine zwitterion. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N[C@@H](CO)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 56-45-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL11298 |
| ChEBI ID | 17115 |
| PubChem CID | 5951 |
| DrugBank | DB00133 |
| UNII ID | VI4F0K069V (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
SLC1A5
SLC1A5
GRIN1
GRIN1
GRIN2B
GRIN2B
Organism
Homo sapiens
Gene name
SLC1A5
Gene synonyms
ASCT2, M7V1, RDR, RDRC
NCBI Gene ID
Protein name
neutral amino acid transporter B(0)
Protein synonyms
Alanine/serine/cysteine transporter 2, ASC amino acid transporter-2, ATB(0), Baboon M7 virus receptor, neutral amino acid transporter B, RD114 virus receptor, RD114/simian type D retrovirus receptor, Sodium-dependent neutral amino acid transporter type 2, solute carrier family 1 (neutral amino acid transporter), member 5, Solute carrier family 1 member 5
Uniprot ID
Mouse ortholog
Slc1a5 (20514)
neutral amino acid transporter B(0) (P51912)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 493,808 documents
View more details
Safety
Black-box Warning
Black-box warning for: Aminosyn ii, Enlyte
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,979 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use